ES2081102T5 - Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado. - Google Patents

Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.

Info

Publication number
ES2081102T5
ES2081102T5 ES92906441T ES92906441T ES2081102T5 ES 2081102 T5 ES2081102 T5 ES 2081102T5 ES 92906441 T ES92906441 T ES 92906441T ES 92906441 T ES92906441 T ES 92906441T ES 2081102 T5 ES2081102 T5 ES 2081102T5
Authority
ES
Spain
Prior art keywords
hsv
glicoprotein
disabled
lipid
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906441T
Other languages
English (en)
Other versions
ES2081102T3 (es
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2081102(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of ES2081102T3 publication Critical patent/ES2081102T3/es
Application granted granted Critical
Publication of ES2081102T5 publication Critical patent/ES2081102T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTAN NUEVAS FORMULACIONES PARA UNA VACUNA CONTRA EL VIRUS DEL HERPES SIMPLE (HSV). ESTAS CONTIENEN UNA GLICOPROTEINA GD DEL HSV O FRAGMENTOS INMUNOLOGICOS JUNTO CON UN LIPIDO A DE MONOFOSFORILO DESACILADO EN LA POSICION 3.
ES92906441T 1991-03-21 1992-03-17 Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado. Expired - Lifetime ES2081102T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine

Publications (2)

Publication Number Publication Date
ES2081102T3 ES2081102T3 (es) 1996-02-16
ES2081102T5 true ES2081102T5 (es) 2001-09-01

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906441T Expired - Lifetime ES2081102T5 (es) 1991-03-21 1992-03-17 Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.

Country Status (34)

Country Link
US (1) US6027730A (es)
EP (1) EP0576478B2 (es)
JP (1) JP3530526B2 (es)
KR (1) KR100224329B1 (es)
CN (2) CN1058191C (es)
AP (1) AP298A (es)
AT (1) ATE129160T1 (es)
AU (1) AU650521B2 (es)
BR (1) BR9205745A (es)
CA (1) CA2106492C (es)
CY (1) CY1936A (es)
CZ (1) CZ280505B6 (es)
DE (1) DE69205566T3 (es)
DK (1) DK0576478T4 (es)
ES (1) ES2081102T5 (es)
FI (1) FI107881B (es)
GB (1) GB9105992D0 (es)
GR (1) GR3017884T3 (es)
HK (1) HK1004525A1 (es)
HU (1) HU218025B (es)
IE (1) IE69560B1 (es)
IL (1) IL101290A (es)
MA (1) MA22471A1 (es)
MX (1) MX9201245A (es)
MY (1) MY110086A (es)
NO (1) NO307499B1 (es)
NZ (1) NZ242057A (es)
PL (1) PL170059B1 (es)
PT (1) PT100262B (es)
SA (1) SA92120459B1 (es)
SK (1) SK279190B6 (es)
WO (1) WO1992016231A1 (es)
YU (1) YU28392A (es)
ZA (1) ZA922011B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US7090842B1 (en) 1994-12-28 2006-08-15 Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
KR101359930B1 (ko) 2004-09-22 2014-02-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물
US20090081253A1 (en) 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
NZ569168A (en) 2005-12-22 2012-02-24 Glaxosmithkline Biolog Sa Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
DK2437753T3 (en) 2009-06-05 2016-12-19 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2010333749B2 (en) 2009-12-21 2015-07-30 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
JP6309274B2 (ja) * 2011-03-11 2018-04-11 ターンストーン・リミテッド・パートナーシップ ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2850431B1 (en) 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
US9566325B2 (en) 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0289550B1 (en) * 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
EP0560776B1 (en) * 1990-08-01 2000-02-09 Research Corporation Technologies, Inc. The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
EP0541692B1 (en) * 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
ES2108278T3 (es) * 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
SA92120459B1 (ar) 2005-06-14
BR9205745A (pt) 1994-10-18
NO307499B1 (no) 2000-04-17
CN1101226C (zh) 2003-02-12
GB9105992D0 (en) 1991-05-08
CN1201692A (zh) 1998-12-16
WO1992016231A1 (en) 1992-10-01
GR3017884T3 (en) 1996-01-31
PT100262B (pt) 2001-05-31
NO933343D0 (no) 1993-09-20
EP0576478B2 (en) 2001-04-18
IL101290A (en) 1996-07-23
HU218025B (hu) 2000-05-28
JPH06505727A (ja) 1994-06-30
FI934134A0 (fi) 1993-09-21
ES2081102T3 (es) 1996-02-16
NO933343L (no) 1993-09-20
CA2106492A1 (en) 1992-09-22
IE69560B1 (en) 1996-10-02
PL170059B1 (pl) 1996-10-31
JP3530526B2 (ja) 2004-05-24
CZ280505B6 (cs) 1996-02-14
YU28392A (sh) 1994-11-15
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
PT100262A (pt) 1993-06-30
ATE129160T1 (de) 1995-11-15
DK0576478T3 (da) 1995-12-04
HUT67052A (en) 1995-01-30
KR100224329B1 (ko) 1999-10-15
SK94693A3 (en) 1994-05-11
ZA922011B (en) 1993-01-27
HK1004525A1 (en) 1998-11-27
IE920881A1 (en) 1992-09-23
FI934134A (fi) 1993-09-21
AU650521B2 (en) 1994-06-23
AP9200368A0 (en) 1992-04-30
DE69205566D1 (en) 1995-11-23
DE69205566T3 (de) 2002-09-05
MY110086A (en) 1997-12-31
DK0576478T4 (da) 2001-07-23
MX9201245A (es) 1992-10-01
SK279190B6 (sk) 1998-07-08
CY1936A (en) 1992-03-17
CZ195893A3 (en) 1994-07-13
IL101290A0 (en) 1992-11-15
HU9302645D0 (en) 1994-01-28
US6027730A (en) 2000-02-22
CN1065997A (zh) 1992-11-11
EP0576478A1 (en) 1994-01-05
DE69205566T2 (de) 1996-04-18
CN1058191C (zh) 2000-11-08
NZ242057A (en) 1993-12-23
AP298A (en) 1994-01-14
EP0576478B1 (en) 1995-10-18
FI107881B (fi) 2001-10-31
MA22471A1 (fr) 1992-10-01

Similar Documents

Publication Publication Date Title
ES2081102T5 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
GB2303854B (en) Helicobacter proteins and vaccines
ES2113882T3 (es) Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.
DE69425427D1 (de) Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
AU8762991A (en) Human papilloma viral protein expression for use in vaccine compositions
GR3030834T3 (en) Herpes simplex virus vp16 vaccines
ATE118353T1 (de) Rekombinanter herpes simplex gb-gd impfstoff.
SE9600647D0 (sv) Ny användning
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
HK1005541A1 (en) Treatment of helicobacter associated gastroduodenal disease
SE8401537L (sv) Forbettrade analgetiska och anti-inflammatoriska kompositioner innefattande ibuprofen och sett att anvenda dessa
ATE149091T1 (de) Einen tetra-polyol enthaltendes impfstoff- adjuvans
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DK0471726T4 (da) Acellulær vaccine
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
MY128929A (en) Vaccine against hepatitis a and hepatitis b
ES2057008T3 (es) Medicamento.
ATE165620T1 (de) Impfstoffe auf basis geänderter boviner herpesviren typ 1
AR241574A1 (es) Procedimiento para preparar una nueva composicion farmaceutica para tratar la insuficiencia cardiaca.
ES482549A0 (es) Un metodo para la preparacion de una composicion de virus herpes
IT1237795B (it) Fattori di crescita fibroblastici per l'uso nella prevenzione e nel trattamento di infezioni virali.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 576478

Country of ref document: ES